The relationship between the change in UGE and the glucose-lowering efficacy of SGLT-2 inhibitors in patients with type 2 diabetes mellitus has been researched; however, the conclusions drawn are inconsistent. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.